Skip to Main Content

The addition of the crystal breeder has allowed us to build on the intellectual capabilities that we have in-house by increasing throughput and efficiency, while saving on resources.

The continuous addition of new technologies keeps PLS at the front of early-phase development expertise. With the ability to perform solid form screens and solubility studies at 0.1 mL scale we can save time, resources and overall project costs. We have repeatedly proven to be a valuable partner to help progress candidates through clinic efficiently.

Check out this video with our expert, Frank Koppenhagen, Ph.D., discussing the capabilities and advantages of this new instrumentation.

Additional Articles

Pace Analytical® Acquires Emerson Resources, Inc. Adding Clinical Trial Material Production Capabilities

August 25, 2020

Pace Analytical® Chief Compliance Officer to Honor the 50th Anniversary of the EPA at the National Environmental Monitoring Conference

August 4, 2020